Table 1. Clinical characteristics and surgical parameters of patients who underwent 23-gauge transconjunctival sutureless vitrectomy and 20-gauge pars plana vitrectomy.
| Parameters | 23-Gauge vitrectomy (n=338) | 20-Gauge vitrectomy (n=476) | P-value |
|---|---|---|---|
| Age at operation (years) | 59.2±12.3 (range: 5–85) | 56.7±13.8 (range: 10–87) | 0.007 |
| Gender (M:F) | 133 : 205 | 234 : 242 | 0.006 |
| Intraoperative sclerotomy suture | 42 (12.4%) | 476 (100%) | <0.001 |
| Gas tamponade | 86 (25.4%) | 156 (32.8%) | 0.024 |
| Silicone oil tamponade | 8 (2.4%) | 35 (7.4%) | 0.002 |
| Combined cataract surgery | 130 (38.5%) | 123 (25.8%) | <0.001 |
| Combined scleral buckling or encircling | 5 (1.5%) | 14 (2.9%) | 0.173 |
| Intravitreal triamcinolone injection at the end of vitrectomy | 14 (4.1%) | 16 (3.4%) | 0.560 |
| Preoperative intraocular pressure | 12.8±3.52 | 13.1±4.36 | 0.221 |
| Patients with preoperative glaucoma | 5 (1.5%) | 9 (1.9%) | 0.65 |
| Indications for surgery | |||
| Vitreous hemorrhage/opacity | 80 (23.7%) | 121 (25.4%) | <0.001 |
| Epiretinal membrane | 79 (23.4%) | 45 (9.5%) | |
| Traction retinal detachment | 44 (13.0%) | 97 (20.4%) | |
| Macular hole | 43 (12.7%) | 54 (11.3%) | |
| Rhegmatogenous retinal detachment | 30 (8.9%) | 72 (15.1%) | |
| Macular edema | 20 (5.9%) | 20 (4.2%) | |
| Othersa | 42 (12.4%) | 67 (14.1%) | |
| Number of postoperative IOP-lowering medicationb | None : one : two : three | ||
| Day 1 | 338 : 0 : 0 : 0 | 476 : 0 : 0 : 0 | NA |
| Day 7 (%) | 277 : 23 : 22 : 16 (82.0 : 6.8 : 6.5 : 4.7) | 335 : 81 : 58 : 2 (70.4 : 17.0 : 12.2 : 0.4) | 0.108c |
| Day 30 (%) | 310 : 11 : 11 : 6 (91.7 : 3.3 : 3.3 : 1.8) | 430 : 36 : 10 : 0 (90.3 : 7.6 : 2.1 : 0) | 0.308c |
Abbreviation: NA, not applicable.
a
Others including vitrectomy for vitreomacular traction, retained lens fragment, subretinal hemorrhage, endophthalmitis, retinal vein obstruction, intraocular lens dislocation, and intraocular foreign body.
b
The number only counts the number of instilling medications at the time of measurement. At the time of IOP measurement on day 1, there was no patient who uses IOP-lowering medication because IOP-lowering medication initiated after the measurement.
c
Linear-by-linear association was performed for the statistical evaluation.
Continuous values are expressed as mean±s.d. Bonferroni-adjusted P-value (0.002) was used for evaluating statistical significance.